Dr. May Orfali has a deep and extensive background in drug and clinical development programs that spans two decades in multiple therapeutic areas, with a focus on rare diseases and oncology. Her most recent role was president at Oncology and Rare disease Consulting, LLC, she was the chief medical officer at CANbridge Life Sciences where she led the clinical development and medical affairs group, focused on progressing phase I and phase II oncology assets in glioblastoma multiforme and esophageal cancer, filing NDA for neratinib in china in adjuvant and metastatic breast cancer therapy. Prior to that, she was Executive Director, Global Product Development, Pfizer, Inc., USA, where she was responsible for patient-focused drug development across multiple rare disease assets in hematology, sickle cell disease, hemophilia, endocrinology, gene therapy and TTR-amyloidosis. Prior to her time at Pfizer, Dr. Orfali held several clinical leadership positions, including Senior Director, Global Medical Monitor, Oncology at Wyeth Pharmaceutical Company, USA; VP Clinical Development and Medical Affairs at Artisan Pharma, Inc., USA; Vice President, Clinical Research and Medical Affairs, Aeris Therapeutics, USA; Medical Director, CDMA, Cubist Pharmaceuticals and Medical Director, Women’s Health Group at Boston Scientific Corporation.
Dr. Orfali holds a medical degree from the University of Baghdad, Baghdad, Iraq, and a Pharmaceutical Masters of Business Administration from Cambridge University, Cambridge, England. She was a practicing physician, specialized in CNS Oncology Clinical Research at Dana-Farber Cancer Institute, in Boston, MA and completed her Fellowship in Pediatric Oncology/Hematology at Massachusetts General Hospital and Children’s Hospital, Boston, MA.